Noted This Week

Soon, there may be a new standard of care for patients with previously treated KRAS^G12C-mutated colorectal cancer, researchers announced at the AACR meeting. The phase I/II KRYSTAL-1 trial, which was concurrently published, tested the KRAS^G12C inhibitor adagrasib (Krazati; Mirati) plus the EGFR inhibitor cetuximab (Erbitux) in 94 patients with metastatic disease. The objective response rate was 34%, and the disease control rate was 85.1%, with responses lasting a median of 5.8 months (Cancer Discov 2024 Apr 8 [Epub]). The median progression-free survival (PFS) was 6.9 months, and the median overall survival (OS) was 15.9 months. The study did not test the combination against adagrasib alone, but the researchers said that the drug duo compared favorably with historical data.

More Noted This Week, April 5–11   »